Ubs Group Ag Inhibrx, Inc. Transaction History

Ubs Group Ag

$397 Billion
Q1 2024

A detailed history of Ubs Group Ag transactions in Inhibrx, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 445,197 shares of INBX stock, worth $6.31 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

445,197

Previous 80,785 451.09%

Holding current value

$6.31 Million

Previous $3.07 Million 407.14%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$32.76 - $39.56 $11.9 Million - $14.4 Million	364,412 Added 451.09%	445,197 $15.6 Million
Q4 2023 Feb 09, 2024	BUY	$14.5 - $38.0 $620,339 - $1.63 Million	42,782 Added 112.58%	80,785 $3.07 Million
Q3 2023 Nov 09, 2023	BUY	$15.75 - $26.31 $570,024 - $952,211	36,192 Added 1998.45%	38,003 $697,000
Q2 2023 Aug 11, 2023	SELL	$16.96 - $27.82 $800,020 - $1.31 Million	-47,171 Reduced 96.3%	1,811 $47,000
Q1 2023 May 12, 2023	SELL	$18.45 - $27.14 $742,889 - $1.09 Million	-40,265 Reduced 45.12%	48,982 $924,000

Q4 2022 Feb 08, 2023	BUY	$20.18 - $33.33 $1.44 Million - $2.38 Million	71,452 Added 401.53%	89,247 $2.2 Million
Q3 2022 Nov 10, 2022	BUY	$11.58 - $24.73 $206,066 - $440,070	17,795 New	17,795 $319,000
Q2 2022 Aug 10, 2022	SELL	$8.52 - $25.26 $275,562 - $816,984	-32,343 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$19.89 - $43.18 $91,792 - $199,275	-4,615 Reduced 12.49%	32,343 $721,000
Q4 2021 Feb 14, 2022	BUY	$26.75 - $46.02 $988,626 - $1.7 Million	36,958 New	36,958 $1.61 Million
Q2 2021 Aug 13, 2021	SELL	$14.69 - $27.52 $37,048 - $69,405	-2,522 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$16.27 - $41.26 $9,696 - $24,590	596 Added 30.94%	2,522 $51,000
Q4 2020 Feb 11, 2021	BUY	$15.96 - $50.0 $13,390 - $41,950	839 Added 77.18%	1,926 $64,000
Q3 2020 Nov 12, 2020	BUY	$16.77 - $20.65 $18,228 - $22,446	1,087 New	1,087 $20,000

Others Institutions Holding INBX

# of Institutions

132

Shares Held

35.5M

Call Options Held

64.8K

Put Options Held

91.3K

View Full List

About Inhibrx, Inc.

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $553M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

More about INBX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account